![]() | |
Names | |
---|---|
Preferred IUPAC name 1-(3,4-Dichlorophenyl)-2-[(propan-2-yl)amino]ethan-1-ol | |
Other names 1-(3,4-Dichlorophenyl)-2-(isopropylamino)ethanol Dichlorisoproterenol | |
Identifiers | |
| |
3D model (JSmol) | |
ChEBI | |
ChEMBL | |
ChemSpider | |
KEGG |
|
MeSH | Dichloroisoproterenol |
UNII | |
| |
| |
Properties | |
C11H15Cl2NO | |
Molar mass | 248.15 g/mol |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). |
Dichloroisoprenaline (DCI), also known asdichloroisoproterenol, was the firstbeta blocker ever to be developed. It is non-selective for theβ1-adrenergic andβ2-adrenergic receptors. DCI has lowpotency and acts as apartial agonist/antagonist at thesereceptors.[1]
Although DCI was of no clinical value itself, further developments from DCI eventually led to the development of the clinical candidatepronethalol (withdrawn due tocarcinogenicity) and subsequentlypropranolol (the first clinically successful beta blocker).
Dichloroisoprenaline is aracemic mixture ofenantiomers.
![]() | This article about anorganic compound is astub. You can help Wikipedia byexpanding it. |